Pedro Antonio Cascales Campos
Full Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (20)
Importance Ovarian cancer, often diagnosed at advanced stages, presents significant challenges in treatment and survival. Evaluation of different hyperthermic intraperitoneal chemotherapy (HIPEC) regimens could provide crucial insights to improve patient outcomes. Objective To evaluate whether HIPEC with paclitaxel (HIPEC-paclitaxel) is associated with similar oncological outcomes as HIPEC with cisplatin (HIPEC-cisplatin) in patients with advanced ovarian cancer undergoing interval cytoreductive surgery (iCRS). Design, Setting, and Participants This multicenter retrospective cohort study included patients with advanced ovarian cancer who received iCRS and HIPEC. Patients with primary or secondary surgical procedures or nonovarian cancers were excluded. Data came from the National Registry of Peritoneal Carcinomatosis, which includes 27 Spanish specialized peritoneal oncology centers. Cases were included from January 2012 to December 2022. The study used propensity score matching to balance the groups and ensure comparability. Exposure HIPEC-cisplatin and HIPEC-paclitaxel, administered during iCRS. The HIPEC regimen was selected based on the standard clinical protocol for advanced ovarian cancer. Main Outcomes and Measures The primary end points were overall survival (OS) and disease-free survival (DFS). The secondary end point was the rate of complications in each group. These outcomes were predefined prior to data collection. Results A total of 846 patients (mean [SD] age, 59.04 [11.01] years) were included (325 [38.4%] in HIPEC-cisplatin group; 521 [61.6%] in HIPEC-paclitaxel group), and 199 patients in each group were propensity score matched. Among these 398 matched patients, the HIPEC-paclitaxel group had similar DFS and OS compared with the HIPEC-cisplatin group. Additionally, similar morbidity was observed. Equivalence in OS and DFS was observed during the initial 20 and 15 months of follow-up, respectively, with an equivalence margin of 0.1 respectively. Conclusions and Relevance In this cohort study of patients with advanced ovarian cancer, HIPEC-paclitaxel was associated with comparable oncologic outcomes as HIPEC-cisplatin, suggesting that it could be a viable alternative. These findings support its use, especially in patients in whom cisplatin could be contraindicated. Further studies may help refine treatment protocols and improve patient-specific outcomes.
Year:
2025
Backgroud: Ovarian cancer is the deadliest gynecologic malignancy, with most patients presenting with peritoneal dissemination at diagnosis. Complete cytoreduction and sensitivity to platinum-based systemic chemotherapy remain the most significant prognostic factors. However, even after optimal first-line management, over half of patients relapse due to residual microscopic disease. Intraperitoneal chemotherapy aims to target this component, with normothermic intraperitoneal chemotherapy long-term (NIPEC-LT) and hyperthermic intraperitoneal chemotherapy (HIPEC) being the most studied approaches. While NIPEC-LT has demonstrated improved survival in select trials, concerns regarding toxicity and catheter-related complications have limited its adoption as standard care. Conversely, HIPEC has shown survival benefits, particularly in patients undergoing interval cytoreductive surgery (iCRS) after neoadjuvant chemotherapy, leading to its inclusion in clinical guidelines. However, HIPEC is administered as a single intraoperative treatment, limiting its prolonged effect. Objectives and Method: This study investigates the combination of HIPEC and postoperative NIPEC-LT in the BICOV-1 trial, a prospective, non-randomized phase I study evaluating the feasibility, safety, and oncologic outcomes. The primary objective is to assess the treatment completion rates and morbidity. The secondary endpoints include disease-free survival (DFS), overall survival (OS), and quality-of-life measures. Combining HIPEC and NIPEC-LT is a rational approach, as both have shown independent benefits and do not overlap in toxicity. HIPEC-induced biological changes may enhance the effectiveness of subsequent intraperitoneal chemotherapy. This trial will provide essential data for future phase II/III studies assessing the role of intensified intraperitoneal treatment in ovarian cancer management.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Background: This study aimed to analyze the morbidity, mortality, and survival outcomes in patients with peritoneal surface malignancies who were initially considered candidates for cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) but were found to have unresectable disease, resulting in nontherapeutic exploratory laparotomy. Patients and Methods: We evaluated data from our referral center for the treatment of peritoneal surface malignancies between January 2008 and December 2022. Adverse events following nontherapeutic laparotomy were classified using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Results: Among a cohort of 486 patients with peritoneal surface malignancies initially considered candidates for CRS + HIPEC, 46 cases (9.4%) were aborted due to the disease being deemed unresectable during exploratory laparotomy. The primary reasons for unresectability included extensive disease spread, observed in 28 patients, with massive small intestine involvement detected in 13 of these cases. The median duration of surgery was 90 min (range: 60–180 min). Postoperative complications occurred in 10 patients (22%), with a mortality rate of 4.3% (2 patients). Survival was significantly lower in patients who did not receive adjuvant systemic chemotherapy with palliative intent (4 months vs. 15 months, p < 0.01). Conclusions: Exploratory laparotomy in patients with peritoneal surface malignancies considered for CRS with HIPEC carries a substantial risk of complications. Improved preoperative staging using advanced technologies such as radiomics and laparoscopy is expected to reduce the number of patients undergoing nontherapeutic laparotomy.
Year:
2025
Year:
2025
Background and Objectives Intraperitoneal chemotherapy can be administered as a single dose associated with hyperthermia (HIPEC) or in successive doses under normothermic conditions, such as early postoperative intraperitoneal chemotherapy (EPIC) or normothermic intraperitoneal chemotherapy (NIPEC or NIPEC‐LT). Repetitive administration of intraperitoneal chemotherapy over a prolonged period may be associated with catheter‐related complications, which are the primary cause of treatment interruption. This study aims to introduce and evaluate an innovative catheter system designed to mitigate these issues. Methods Using a porcine experimental model, we tested a new catheter for long‐term intraperitoneal access. Sixteen animals underwent catheter implantation followed by normothermic recirculation of peritoneal dialysis solution. Catheter functionality and any complications were monitored throughout successive treatment cycles. Results The new catheter system demonstrated optimal recirculation and maintained its functionality throughout successive treatments, without complications. Catheter replacement with a guidewire was successful, ensuring continued efficacy. Conclusions The innovative catheter system shows promise in reducing complications and improving compliance in successive intraperitoneal chemotherapy doses, justifying further clinical trials to confirm its efficacy in patients.
Year:
2024
Deceased donor liver transplantation (LT) is a crucial lifesaving option for patients with end-stage liver diseases. Although donation after brain death (DBD) remains the main source of donated organs, exploration of donation after circulatory death (DCD) addresses donor scarcity but introduces challenges due to warm ischemia. While technical advances have improved outcomes, challenges persist, with a 13% mortality rate within the first year. Delving into liver transplantation complexities reveals the profound impact of molecular signaling on organ fate. NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome activation play a pivotal role, influencing inflammatory responses. The NLRP3 inflammasome, found in hepatocytes, contributes to inflammation, fibrosis, and liver cell death. This study explores these dynamics, shedding light on potential biomarkers and therapeutic targets. Samples from 36 liver transplant patients were analyzed for ASC specks detection and inflammasome-related gene expression. Liver biopsies, obtained before and after cold ischemia storage, were processed for immunofluorescence, qRT-PCR, and Western blot. One year post-LT clinical follow-up included diagnostic procedures for complications, and global survival was assessed. Immunofluorescence detected activated inflammasome complexes in fixed liver tissues. ASC specks were identified in hepatocytes, showing a trend toward more specks in DCD livers. Likewise, inflammasome-related gene expression analysis indicated higher expression in DCD livers, decreasing after cold ischemia. Similar results were found at protein level. Patients with increased ASC specks staining exhibited lower overall survival rates, correlating with IL1B expression after cold ischemia. Although preliminary, these findings offer novel insights into utilizing direct detection of inflammasome activation in liver tissue as a biomarker. They suggest its potential impact on post-transplant outcomes, potentially paving the way for improved diagnostic approaches and personalized treatment strategies in LT.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (13)
Anna Serra Rubert
Profesora asociada asistencial
Universitat Jaume I
Álvaro Arjona-Sánchez
-
Berta Díaz-Feijoo
Head of the Gynecology Department, Hospital Clinic Barcelona (Spain)
University of Barcelona
Enrique Aranda Aguilar
Catedrático
Universidad de Córdoba
Laura Martinez-Alarcon
Universidad de Murcia
A Rios
Catedrático
Universidad de Murcia
José Antonio Pons-Miñano
Professor of Gastroenterology and Hepatology. Chief of Hepatology. Liver Transplnt Unit
Hospital Universitario Virgen del Rocío
Ruth Vera
Chief of the department
Hospital Universitari Arnau de Vilanova
Luis González Bayón
Profesor Titular Patología Quirúrgica
Universidad Complutense de Madrid
Antoni Llueca
Professor
Universitat Jaume I
Antonio Gil-Moreno
University of Barcelona
Juan José Segura-Sampedro
Profesor Clínico Titular
Universidad CEU San Pablo
pedro villarejo campos
Associate Professor
Universidad Complutense de Madrid Facultad de Medicina
Make your next move.
Prepare your application
Review drafts before you send them.